Physician profile
Gautham Viswanathan
NPI 1427194257
$9,654.63
in general payments reported to CMS, 2019-2025
22 companies · $372 in 2025
The $372 reported for 2025 was more than what a typical Nephrology (Internal Medicine) provider received nationally (typical 2025 total: $311).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $267 · 2020: $153 · 2021: $435 · 2022: $3,954 · 2023: $3,972 · 2024: $503 · 2025: $372.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Consulting Fee: $3,444 · Food and Beverage: $1,357 · Education: $46.43.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Consulting Fee | $3,443.50 |
| Food and Beverage | $1,356.81 |
| Education | $46.43 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Otsuka America Pharmaceutical, INC. | $3,766.49 | 2019-2025 | Jynarque, Tolvaptan |
| Travere Therapeutics, INC. | $3,635.51 | 2019-2025 | Filspari |
| Fresenius USA Marketing, INC. | $445.47 | 2019-2024 | Velphoro |
| Akebia Therapeutics INC | $347.25 | 2019-2024 | Vafseo, Auryxia |
| Novartis Pharmaceuticals Corporation | $280.55 | 2024-2025 | |
| Novo Nordisk INC | $258.88 | 2021-2024 | Ozempic, Rybelsus |
| Amgen INC. | $211.78 | 2020-2025 | Tavneos |
| Astrazeneca Pharmaceuticals LP | $142.02 | 2019-2021 | |
| Bayer Healthcare Pharmaceuticals INC. | $136.19 | 2021-2023 | |
| Glaxosmithkline, LLC. | $65.28 | 2022-2024 | Benlysta |
| Vifor Pharma, INC. | $58.88 | 2019-2025 | Veltassa |
| Opko Pharmaceuticals, LLC | $57.29 | 2020-2022 | |
| Aurinia Pharma U.S., INC. | $48.56 | 2021-2024 | Lupkynis |
| Mallinckrodt Hospital Products INC. | $47.39 | 2021-2025 | Terlivaz |
| Cormedix INC. | $32.12 | 2024 | Defencath |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ani Pharmaceuticals, INC. | $23.21 | 2022 | |
| Ultragenyx Pharmaceutical INC. | $19.97 | 2021 | |
| Abbvie INC. | $17.09 | 2021 | |
| Daiichi Sankyo INC. | $16.61 | 2021 | |
| Merck Sharp & Dohme LLC | $16.03 | 2023 | Prevymis |
| Scpharmaceuticals INC. | $15.81 | 2025 | |
| Medtronic Vascular, INC. | $12.25 | 2020 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gautham Viswanathan listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.